MPM Bioimpact LLC purchased a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 559,547 shares of the company's stock, valued at approximately $3,452,000. MPM Bioimpact LLC owned about 0.99% of Design Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the business. American Century Companies Inc. boosted its position in Design Therapeutics by 19.9% in the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company's stock valued at $241,000 after buying an additional 6,481 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Design Therapeutics by 186.9% in the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company's stock valued at $219,000 after buying an additional 26,503 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Design Therapeutics by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company's stock valued at $1,633,000 after buying an additional 7,243 shares during the last quarter. Barclays PLC boosted its position in Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company's stock valued at $520,000 after buying an additional 24,602 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Design Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 761,640 shares of the company's stock valued at $4,700,000 after buying an additional 3,090 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.
Design Therapeutics Stock Performance
NASDAQ DSGN traded up $0.15 during trading hours on Friday, reaching $3.51. The stock had a trading volume of 70,352 shares, compared to its average volume of 187,283. The stock has a fifty day moving average of $3.88 and a 200 day moving average of $4.89. The stock has a market cap of $199.26 million, a P/E ratio of -4.13 and a beta of 1.77. Design Therapeutics, Inc. has a 52-week low of $2.60 and a 52-week high of $7.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, equities research analysts forecast that Design Therapeutics, Inc. will post -0.91 EPS for the current year.
Design Therapeutics Company Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
